Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals

V. J. Nijenhuis; P. R. Stella; J. Baan; B. R. G. Brueren; P. P. de Jaegere; P. den Heijer; S. H. Hofma; P. Kievit; T. Slagboom; A. F. M. van den Heuvel; F. van der Kley; L. van Garsse; K. G. van Houwelingen; A. W. J. van't Hof; J. M. ten Berg

doi:https://doi.org/10.1007/s12471-013-0496-6

Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals

V. J. Nijenhuis, P. R. Stella, J. Baan, B. R. G. Brueren, P. P. de Jaegere, P. den Heijer, S. H. Hofma, P. Kievit, T. Slagboom, A. F. M. van den Heuvel, F. van der Kley, L. van Garsse, K. G. van Houwelingen, A. W. J. van't Hof, J. M. ten Berg

Research output: Contribution to journal › Article › Academic › peer-review

23 Citations (Scopus)

Abstract

To assess current antithrombotic treatment strategies in the Netherlands in patients undergoing transcatheter aortic valve implantation (TAVI). For every Dutch hospital performing TAVI (n = 14) an interventional cardiologist experienced in performing TAVI was interviewed concerning heparin, aspirin, thienopyridine and oral anticoagulation treatment in patients undergoing TAVI. The response rate was 100 %. In every centre, a protocol for antithrombotic treatment after TAVI was available. Aspirin was prescribed in all centres, concomitant clopidogrel was prescribed 13 of the 14 centres. Duration of concomitant clopidogrel was 3 months in over two-thirds of cases. In 2 centres, duration of concomitant clopidogrel was based upon type of prosthesis: 6 months versus 3 months for supra-annular and intra-annular prostheses, respectively. Leaning on a small basis of evidence and recommendations, the antithrombotic policy for patients undergoing TAVI is highly variable in the Netherlands. As a standardised regimen might further reduce haemorrhagic complications, large randomised clinical trials may help to establish the most appropriate approach

Original language	English
Pages (from-to)	64-69
Journal	Netherlands heart journal
Volume	22
Issue number	2
DOIs	https://doi.org/10.1007/s12471-013-0496-6
Publication status	Published - 2014

Access to Document

https://doi.org/10.1007/s12471-013-0496-6

Cite this

Nijenhuis, V. J., Stella, P. R., Baan, J., Brueren, B. R. G., de Jaegere, P. P., den Heijer, P., Hofma, S. H., Kievit, P., Slagboom, T., van den Heuvel, A. F. M., van der Kley, F., van Garsse, L., van Houwelingen, K. G., van't Hof, A. W. J., & ten Berg, J. M. (2014). Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals. Netherlands heart journal, 22(2), 64-69. https://doi.org/10.1007/s12471-013-0496-6

@article{0b4b2de714e04058ac81045a803669c1,

title = "Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals",

abstract = "To assess current antithrombotic treatment strategies in the Netherlands in patients undergoing transcatheter aortic valve implantation (TAVI). For every Dutch hospital performing TAVI (n = 14) an interventional cardiologist experienced in performing TAVI was interviewed concerning heparin, aspirin, thienopyridine and oral anticoagulation treatment in patients undergoing TAVI. The response rate was 100 %. In every centre, a protocol for antithrombotic treatment after TAVI was available. Aspirin was prescribed in all centres, concomitant clopidogrel was prescribed 13 of the 14 centres. Duration of concomitant clopidogrel was 3 months in over two-thirds of cases. In 2 centres, duration of concomitant clopidogrel was based upon type of prosthesis: 6 months versus 3 months for supra-annular and intra-annular prostheses, respectively. Leaning on a small basis of evidence and recommendations, the antithrombotic policy for patients undergoing TAVI is highly variable in the Netherlands. As a standardised regimen might further reduce haemorrhagic complications, large randomised clinical trials may help to establish the most appropriate approach",

author = "Nijenhuis, {V. J.} and Stella, {P. R.} and J. Baan and Brueren, {B. R. G.} and {de Jaegere}, {P. P.} and {den Heijer}, P. and Hofma, {S. H.} and P. Kievit and T. Slagboom and {van den Heuvel}, {A. F. M.} and {van der Kley}, F. and {van Garsse}, L. and {van Houwelingen}, {K. G.} and {van't Hof}, {A. W. J.} and {ten Berg}, {J. M.}",

year = "2014",

doi = "https://doi.org/10.1007/s12471-013-0496-6",

language = "English",

volume = "22",

pages = "64--69",

journal = "Netherlands heart journal",

issn = "1568-5888",

publisher = "Bohn Stafleu van Loghum",

number = "2",

}

Nijenhuis, VJ, Stella, PR, Baan, J, Brueren, BRG, de Jaegere, PP, den Heijer, P, Hofma, SH, Kievit, P, Slagboom, T, van den Heuvel, AFM, van der Kley, F, van Garsse, L, van Houwelingen, KG, van't Hof, AWJ & ten Berg, JM 2014, 'Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals', Netherlands heart journal, vol. 22, no. 2, pp. 64-69. https://doi.org/10.1007/s12471-013-0496-6

TY - JOUR

T1 - Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals

AU - Nijenhuis, V. J.

AU - Stella, P. R.

AU - Baan, J.

AU - Brueren, B. R. G.

AU - de Jaegere, P. P.

AU - den Heijer, P.

AU - Hofma, S. H.

AU - Kievit, P.

AU - Slagboom, T.

AU - van den Heuvel, A. F. M.

AU - van der Kley, F.

AU - van Garsse, L.

AU - van Houwelingen, K. G.

AU - van't Hof, A. W. J.

AU - ten Berg, J. M.

PY - 2014

Y1 - 2014

N2 - To assess current antithrombotic treatment strategies in the Netherlands in patients undergoing transcatheter aortic valve implantation (TAVI). For every Dutch hospital performing TAVI (n = 14) an interventional cardiologist experienced in performing TAVI was interviewed concerning heparin, aspirin, thienopyridine and oral anticoagulation treatment in patients undergoing TAVI. The response rate was 100 %. In every centre, a protocol for antithrombotic treatment after TAVI was available. Aspirin was prescribed in all centres, concomitant clopidogrel was prescribed 13 of the 14 centres. Duration of concomitant clopidogrel was 3 months in over two-thirds of cases. In 2 centres, duration of concomitant clopidogrel was based upon type of prosthesis: 6 months versus 3 months for supra-annular and intra-annular prostheses, respectively. Leaning on a small basis of evidence and recommendations, the antithrombotic policy for patients undergoing TAVI is highly variable in the Netherlands. As a standardised regimen might further reduce haemorrhagic complications, large randomised clinical trials may help to establish the most appropriate approach

AB - To assess current antithrombotic treatment strategies in the Netherlands in patients undergoing transcatheter aortic valve implantation (TAVI). For every Dutch hospital performing TAVI (n = 14) an interventional cardiologist experienced in performing TAVI was interviewed concerning heparin, aspirin, thienopyridine and oral anticoagulation treatment in patients undergoing TAVI. The response rate was 100 %. In every centre, a protocol for antithrombotic treatment after TAVI was available. Aspirin was prescribed in all centres, concomitant clopidogrel was prescribed 13 of the 14 centres. Duration of concomitant clopidogrel was 3 months in over two-thirds of cases. In 2 centres, duration of concomitant clopidogrel was based upon type of prosthesis: 6 months versus 3 months for supra-annular and intra-annular prostheses, respectively. Leaning on a small basis of evidence and recommendations, the antithrombotic policy for patients undergoing TAVI is highly variable in the Netherlands. As a standardised regimen might further reduce haemorrhagic complications, large randomised clinical trials may help to establish the most appropriate approach

U2 - https://doi.org/10.1007/s12471-013-0496-6

DO - https://doi.org/10.1007/s12471-013-0496-6

M3 - Article

C2 - 24287807

SN - 1568-5888

VL - 22

SP - 64

EP - 69

JO - Netherlands heart journal

JF - Netherlands heart journal

IS - 2

ER -